Novartis India Limited

NOVARTIND

INE234A01025

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 06:00:53 2024-07-16 EDT			5-day change	1st Jan Change
1,172 ^INR	+0.26%		+2.37%	+51.56%

05-10	Novartis India Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	CI
05-10	Novartis India Limited Recommends Dividend for the Financial Year Ended March 31, 2023, Payable on or After August 5, 2024	CI

Tranche Update on Novartis India Limited's Equity Buyback Plan announced on September 25, 2017.

January 29, 2018 at 06:26 am

From September 25, 2017 to January 17, 2018, the company has repurchased 3,450,000 shares, representing 12.26% for INR 2,311.5 million. With this, the company has completed the repurchase of 3,450,000 shares, representing 12.26% for INR 2,311.5 million under the buyback announced on September 25, 2017.

Latest news about Novartis India Limited

Novartis India Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	05-10	CI
Novartis India Limited Recommends Dividend for the Financial Year Ended March 31, 2023, Payable on or After August 5, 2024	05-10	CI
Novartis India Limited Announces Appointment of Chandni Maru as Company Secretary and Compliance Officer	05-08	CI
Novartis India Limited Announces Resignation of Nikhil Malpani as Company Secretary and Compliance Officer, Effective from April 30, 2024	04-01	CI
Novartis Eyes Sale of Listed Unit in India	03-22	CI
Global markets live: Apple, Nintendo, Super Micro Computer, Currys, ABB...	02-19
Swiss Market Index Closes in the Green on Healthcare Stocks Boost	02-19	MT
Novartis Launches Strategic Review of Listed Indian Business	02-19	MT
Dr. Reddy's Laboratories Denies in Race to Acquire Novartis' Stake in Novartis India	02-19	CI
Dr Reddy's Reportedly May Join Race to Acquire Novartis' India Arm	02-17	CI
Dr Reddy'S In Race To Acquire Novartis AG's Stake In Novartis India - CNBC TV-18	02-17	RE
Novartis India Limited Announces Completion of Tenure of Jai Hiremath as Independent Director, Effective March 31, 2024	02-17	CI
Novartis AG Announces A Strategic Review of India Unit	02-16	CI
Novartis India Limited Announces Resignation of Mr. Sanjay Murdeshwar as Managing Director, Effective April 02, 2024	01-25	CI
Novartis India Limited Announces Resignation of Mr. Sanjay Murdeshwar as Vice-Chairman, Effective April 02, 2024	01-25	CI
Novartis India Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	01-25	CI
Novartis India Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	23-10-26	CI
Novartis India Limited Announces Change in Registered Office Address	23-09-15	CI
Novartis India Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-07-26	CI
Novartis India Limited Proposes One-Time Special Dividend	23-06-30	CI
Pfizer's India unit posts 3% rise in Q4 profit	23-05-15	RE
Novartis India Limited Recommends One-Time Special Dividend for the Financial Year Ended March 31, 2023, Payable on or After August 2, 2023	23-05-10	CI
Novartis India Limited Recommends Dividend for the Financial Year Ended March 31, 2023, Payable on or After August 2, 2023	23-05-10	CI
Novartis India Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023	23-05-10	CI
Novartis India Limited Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-10	CI

Chart Novartis India Limited

Duration

Period

More charts

Company Profile

Novartis India Limited is an India-based company that is engaged in the business of trading of pharmaceuticals. The Company's portfolio of medicines addresses various therapeutic needs, such as cardiovascular, eye care, immunology, metabolic, neuroscience, oncology, respiratory and organ transplant, to meet the medical needs of patients in India. In the bone and pain therapeutic area its brand is Voveran. In the transplantation immunology therapeutic area, the Company's brands include Simulect, Certican, Sandimmun, Neoral and Myfortic. In the neurosciences therapeutic area, its brands include Tegrital and Exelon.

Sector

Pharmaceuticals

Calendar

2024-07-22 - Détachement de for final dividend

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
NOVARTIS INDIA LIMITED	+51.56%	346M
ELI LILLY AND COMPANY	+55.35%	848B
NOVO NORDISK A/S	+31.64%	627B
JOHNSON & JOHNSON	-0.10%	363B
MERCK & CO., INC.	+15.47%	318B
ABBVIE INC.	+13.10%	299B
ASTRAZENECA PLC	+15.51%	243B
NOVARTIS AG	+16.72%	225B
AMGEN INC.	+16.54%	179B
PFIZER, INC.	+4.31%	167B